LBPMedicine(688393)

Search documents
安必平涨2.04%,成交额1651.76万元,主力资金净流出84.47万元
Xin Lang Cai Jing· 2025-09-25 02:25
Core Viewpoint - Anbiping's stock price has shown significant volatility in 2023, with a year-to-date increase of 57.23%, but recent declines in the short term raise concerns about its performance [2]. Financial Performance - As of June 30, 2025, Anbiping reported a revenue of 159 million yuan, a year-on-year decrease of 30.11%, and a net profit attributable to shareholders of -12.5 million yuan, a decline of 176.38% [2]. - The company has distributed a total of 87.8 million yuan in dividends since its A-share listing, with 36.5 million yuan distributed over the past three years [3]. Stock Market Activity - On September 25, Anbiping's stock rose by 2.04% to 27.06 yuan per share, with a trading volume of 16.5 million yuan and a turnover rate of 0.66%, resulting in a total market capitalization of 2.532 billion yuan [1]. - The stock has experienced a net outflow of 844,700 yuan in principal funds, with large orders accounting for 18.17% of total purchases and 23.29% of total sales [1]. Shareholder Structure - As of June 30, 2025, Anbiping had 9,221 shareholders, a decrease of 10.55% from the previous period, with an average of 10,147 circulating shares per shareholder, an increase of 11.80% [2]. - Among the top ten circulating shareholders, Changcheng Consumption Value Mixed A (200006) is the eighth largest, holding 850,000 shares as a new shareholder [3]. Business Overview - Anbiping, established on July 6, 2005, and listed on August 20, 2020, is based in Guangzhou, Guangdong Province, and specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [2]. - The company's revenue composition includes 79.72% from self-produced products, 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [2].
安必平跌2.03%,成交额2391.99万元,主力资金净流出407.04万元
Xin Lang Cai Jing· 2025-09-19 02:36
Core Viewpoint - Anbiping's stock price has experienced fluctuations, with a year-to-date increase of 57% but a recent decline in the last 5 and 20 trading days, indicating potential volatility in investor sentiment and market performance [2]. Financial Performance - As of June 30, 2025, Anbiping reported a revenue of 159 million yuan, a year-on-year decrease of 30.11%, and a net profit attributable to shareholders of -12.5 million yuan, a significant decline of 176.38% [2]. - The company has distributed a total of 87.8 million yuan in dividends since its A-share listing, with 36.5 million yuan distributed over the past three years [3]. Stock Market Activity - On September 19, Anbiping's stock price fell by 2.03% to 27.02 yuan per share, with a trading volume of approximately 23.9 million yuan and a turnover rate of 0.94%, resulting in a total market capitalization of 2.528 billion yuan [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent appearance on February 17, where it recorded a net buy of -6.86 million yuan [2]. Shareholder Information - As of June 30, 2025, Anbiping had 9,221 shareholders, a decrease of 10.55% from the previous period, with an average of 10,147 circulating shares per shareholder, an increase of 11.80% [2]. - Among the top ten circulating shareholders, Changcheng Consumption Value Mixed A (200006) is the eighth largest, holding 850,000 shares as a new shareholder [3]. Business Overview - Anbiping, established on July 6, 2005, and listed on August 20, 2020, is based in Guangzhou, Guangdong Province, and specializes in the research, production, and sales of in vitro diagnostic reagents and instruments [2]. - The company's revenue composition includes 79.72% from self-produced products, 13.11% from purchased products, 5.90% from service income, and 1.27% from other sources [2].
破发股安必平上半年转亏 2020年上市募7亿净利连降4年
Zhong Guo Jing Ji Wang· 2025-09-16 08:16
Core Points - Anbiping (688393.SH) reported a significant decline in revenue and net profit for the first half of 2025, with revenue at 159 million yuan, down 30.11% year-on-year, and a net profit attributable to shareholders of -12.5 million yuan compared to a profit of 16.4 million yuan in the same period last year [1] - The company has experienced a continuous decline in net profit for four consecutive years, with net profits of 84.7 million yuan in 2020, decreasing to 21.3 million yuan in 2024 [1] - Anbiping was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 20, 2020, with an initial issuance of 23.34 million shares at a price of 30.56 yuan per share [1] Financial Performance - For the first half of 2025, Anbiping's net profit excluding non-recurring gains and losses was -14.7 million yuan, down from 10.5 million yuan in the previous year [1] - The company's operating cash flow improved to 19.0 million yuan, compared to -11.3 million yuan in the same period last year [1] - Historical net profits from 2020 to 2024 show a downward trend, with figures of 84.7 million yuan, 79.8 million yuan, 42.7 million yuan, 40.1 million yuan, and 21.3 million yuan respectively [1] IPO and Stock Performance - Anbiping's initial public offering raised a total of 713 million yuan, with a net amount of 640 million yuan after deducting issuance costs, exceeding the original plan by 266 million yuan [2] - The company’s stock reached a peak price of 74.00 yuan on its first trading day but is currently in a state of decline [2] - The funds raised were intended for the construction of a research and production base and the upgrade of the marketing service network [2]
安必平:2025年第一次临时股东大会决议公告
Zheng Quan Ri Bao· 2025-09-09 13:22
Core Points - Anbiping announced the convening of its first extraordinary general meeting of shareholders for 2025 on September 9, 2025 [2] - The meeting approved the proposal to temporarily adjust the use of idle sites for certain fundraising investment projects [2] Summary by Category - **Company Announcement** - Anbiping will hold its first extraordinary general meeting of shareholders for 2025 on September 9, 2025 [2] - **Investment Project Adjustments** - The shareholders' meeting approved a proposal to temporarily adjust the use of idle sites related to certain fundraising investment projects [2]
安必平(688393) - 2025年第一次临时股东大会决议公告
2025-09-09 10:15
证券代码:688393 证券简称:安必平 公告编号:2025-042 广州安必平医药科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 本次会议是否有被否决议案:无 一、 会议召开和出席情况 (一) 股东大会召开的时间:2025 年 9 月 9 日 (二) 股东大会召开的地点:广州市黄埔区科信街 2 号公司会议室 (三) 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况: | 1、出席会议的股东和代理人人数 | 38 | | --- | --- | | 普通股股东人数 | 38 | | 2、出席会议的股东所持有的表决权数量 | 33,600,596 | | 普通股股东所持有表决权数量 | 33,600,596 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 35.9105 | | 例(%) | | | 普通股股东所持有表决权数量占公司表决权数量的比例(%) | 35.9105 | (四) 表决方式是否 ...
安必平(688393) - 广东信达律师事务所关于广州安必平医药科技股份有限公司2025年第一次临时股东大会的法律意见书
2025-09-09 10:02
股东大会法律意见书 達律師事務所 INDIAL LAW FIRM 中国深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮编: 518038 11-12/F, TAIPING FINANCE TOWER, YITIAN ROAD 6001, FUTIAN DISTRICT, SHENZHEN, P.R. CHINA 电话(Tel):(0755)88265288 传真(Fax):(0755)88265537 电子邮件(E-mail): info@sundiallawfirm.com 网址(Website): www.sundiallawfirm.com 广东信达律师事务所 关于广州安必平医药科技股份有限公司 2025 年第一次临时股东大会的法律意见书 信达科会字(2025)第 042 号 1 國國信達律師事務所 股东大会法律意见书 意见书出具日以前已经发生或者存在的事实,严格履行了法定职责,遵循了勤勉 尽责和诚实信用原则,进行了充分的核查验证,保证本法律意见书所认定的事实 真实、准确、完整,所发表的结论性意见合法、准确,不存在虚假记载、误导性 陈述或者重大遗漏,并承担相应法律责任。 本法律意见书仅供 ...
安必平(688393) - 2025年第一次临时股东大会会议资料
2025-08-28 08:21
广州安必平医药科技股份有限公司 2025 年第一次临时股东大会会议资料 公司代码:688393 公司简称:安必平 广州安必平医药科技股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 9 月 广州安必平医药科技股份有限公司 2025 年第一次临时股东大会会议资料 目录 | 2025 | 年第一次临时股东大会会议须知 | 2 | | --- | --- | --- | | 2025 | 年第一次临时股东大会会议议程 | 4 | | 2025 | 年第一次临时股东大会会议议案 | 6 | | | 议案一 关于暂时调整部分募集资金投资项目闲置场地用途的议案 | 6 | 1 广州安必平医药科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益,确保股东大会的正常秩序和议事效率,保证 大会的顺利进行,根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《广州安必平医药科技股份有限公司章程》《广州安 必平医药科技股份有限公司股东大会议事规则》等相关规定,特制定本次股东大 会会议须知: 一、为保证股东大会的 ...
安必平2025年中报简析:净利润同比下降176.38%,公司应收账款体量较大
Zheng Quan Zhi Xing· 2025-08-22 23:18
Core Viewpoint - Anbiping (688393) reported a significant decline in financial performance for the first half of 2025, with total revenue of 159 million yuan, down 30.11% year-on-year, and a net profit attributable to shareholders of -12.5 million yuan, a decrease of 176.38% [1] Financial Performance Summary - Total revenue for Q2 was 86.85 million yuan, reflecting a 31.39% year-on-year decline [1] - The gross margin decreased to 63.12%, down 10.55% year-on-year, while the net margin was -8.64%, a drop of 260.29% [1] - Total expenses (selling, administrative, and financial) reached 103 million yuan, accounting for 64.62% of revenue, an increase of 9.11% year-on-year [1] - Earnings per share were -0.13 yuan, a decrease of 176.47% year-on-year [1] Changes in Financial Items - Cash and cash equivalents decreased by 41.57% due to investments in financial products [2] - Trade financial assets increased by 97.19%, also due to investments in financial products [2] - Accounts receivable surged by 381.52% due to the receipt of notes [2] - Short-term borrowings rose by 102.66% due to increased discounting of letters of credit [2] Revenue and Cost Analysis - Revenue decline of 30.11% attributed to the implementation of centralized procurement policies for HPV products, resulting in a revenue drop of 31.43 million yuan, or 70.71% [3] - Operating costs decreased by 12.44% due to reduced sales volume [3] - Sales expenses fell by 24.27% due to decreased marketing costs [3] - Management expenses decreased by 22.74% due to staff adjustments and reduced stock compensation costs [3] Business Evaluation - The company's return on invested capital (ROIC) was 0.51%, indicating weak capital returns, with a historical median ROIC of 15.71% since its listing [4] - The net profit margin was 3.17%, suggesting low added value for products or services [4] - The business model relies heavily on research and marketing, necessitating further investigation into these driving factors [4] Accounts Receivable Concern - The accounts receivable to net profit ratio reached 902.51%, indicating a significant concern regarding the company's receivables management [5]
安必平:陷集采泥潭由盈转亏,转型三箭齐发难阻原始股东“用脚投票”|看财报
Tai Mei Ti A P P· 2025-08-22 12:10
Core Viewpoint - Anbiping (688393.SH), known as the "first stock in pathological diagnosis," reported its worst half-year performance since its listing, with a significant revenue drop due to the ongoing impact of centralized procurement in the IVD industry [2][3] Company Performance - In the first half of 2025, Anbiping's revenue fell by 30.11% year-on-year to 159 million yuan, and net profit shifted from a profit of 16.36 million yuan in the same period last year to a loss of 12.49 million yuan [2][3] - The core product, HPV testing, saw prices cut by over 50% due to centralized procurement, leading to a 70.71% decline in revenue from this segment [3] Industry Context - The entire IVD industry is experiencing a downturn, with established companies like Dirui Medical forecasting losses for the first time in 11 years, and Maike Biological reporting an 83.12% drop in net profit [3] - Centralized procurement led by Anhui resulted in an average price drop of 53.9% across 25 provinces, with some products seeing reductions of up to 73% [3] Strategic Initiatives - Anbiping is pursuing three strategic paths: building pathology services, embracing digital transformation, and expanding into international markets [5] - The pathology co-construction business showed a rare positive performance, with revenue increasing by 44.49% year-on-year to 11.69 million yuan, marking it as a strategic focus for the company [5] - The digital transformation initiative aims to enhance existing product lines with AI, with projected revenue from this segment exceeding 10 million yuan in 2024, growing over 80% [5] International Expansion - Anbiping received CE certification for 13 IHC and 1 LBP products in the first half of the year and has begun sending samples to multiple countries [6] - While partnerships have been established in several countries, significant challenges remain in product registration and local operations, making it difficult to achieve substantial overseas revenue in the short term [6] Shareholder Activity - Original shareholders have been continuously reducing their stakes, with their ownership dropping from 13.84% to below 5% over two years, signaling potential concerns about the company's transformation efforts [7]
8月22日晚间重要公告一览
Xi Niu Cai Jing· 2025-08-22 10:13
Group 1 - Gujia Home achieved a net profit of 1.02 billion yuan in the first half of 2025, a year-on-year increase of 13.89% [1] - Gujia Home's revenue for the first half of 2025 was 9.80 billion yuan, up 10.02% year-on-year [1] - Phoenix Holdings reported a net profit of 11.04 million yuan, successfully turning a profit [1] - Phoenix Holdings' revenue increased by 200.78% year-on-year to 291 million yuan [1] - Zheshang Securities recorded a net profit of 1.15 billion yuan, a year-on-year growth of 46.49% [1] - Zheshang Securities' revenue decreased by 23.66% to 6.11 billion yuan [1] Group 2 - Tianjin Port's net profit was 503 million yuan, a year-on-year decrease of 18.33% [3] - Tianjin Port's revenue for the first half of 2025 was 6.18 billion yuan, an increase of 4.33% year-on-year [3] - Xuantai Pharmaceutical reported a net profit of 45.59 million yuan, down 15.82% year-on-year [5] - Xuantai Pharmaceutical's revenue was 220 million yuan, a slight increase of 0.74% year-on-year [5] Group 3 - Yilida achieved a net profit of 40.03 million yuan, a year-on-year increase of 18.32% [7] - Yilida's revenue for the first half of 2025 was 758 million yuan, up 12.56% year-on-year [7] - Zhongji United reported a net profit of 262 million yuan, a significant year-on-year increase of 86.61% [9] - Zhongji United's revenue was 818 million yuan, a year-on-year growth of 43.52% [9] Group 4 - China Shipbuilding Special Gas reported a net profit of 178 million yuan, a slight decrease of 0.55% year-on-year [10] - China Shipbuilding Special Gas' revenue was 1.04 billion yuan, an increase of 12.60% year-on-year [10] - Xinyuan Intelligent Manufacturing achieved a net profit of 9.79 million yuan, a year-on-year increase of 284.45% [11] - Xinyuan Intelligent Manufacturing's revenue was 329 million yuan, up 388.33% year-on-year [11] Group 5 - Jiudian Pharmaceutical reported a net profit of 291 million yuan, a year-on-year increase of 2.57% [13] - Jiudian Pharmaceutical's revenue was 1.51 billion yuan, a year-on-year growth of 10.67% [13] - Boya Biological reported a net profit of 225 million yuan, down 28.68% year-on-year [15] - Boya Biological's revenue was 1.01 billion yuan, an increase of 12.51% year-on-year [15] Group 6 - True Love Home achieved a net profit of 197 million yuan, a year-on-year increase of 484.48% [17] - True Love Home's revenue was 390 million yuan, up 21.82% year-on-year [17] - Dongfang Electronics reported a net profit of 302 million yuan, a year-on-year increase of 19.65% [19] - Dongfang Electronics' revenue was 3.16 billion yuan, a year-on-year growth of 12.18% [19] Group 7 - Watte Holdings achieved a net profit of 18.41 million yuan, a year-on-year increase of 23.94% [21] - Watte Holdings' revenue was 906 million yuan, up 12.29% year-on-year [21] - Tianqin Equipment reported a net profit of 16.36 million yuan, a year-on-year increase of 2.78% [22] - Tianqin Equipment's revenue was 111 million yuan, a year-on-year growth of 18.42% [22] Group 8 - Yingfeng Environment achieved a net profit of 382 million yuan, a year-on-year increase of 0.43% [24] - Yingfeng Environment's revenue was 6.46 billion yuan, up 3.69% year-on-year [24] - Kexin Machinery reported a net profit of 52.20 million yuan, a year-on-year decrease of 46.18% [26] - Kexin Machinery's revenue was 592 million yuan, down 17.26% year-on-year [26] Group 9 - Tengda Construction reported a net profit of 108 million yuan, a year-on-year decrease of 0.69% [27] - Tengda Construction's revenue was 1.61 billion yuan, down 5.20% year-on-year [27] - Canaan Technology achieved a net profit of 7.35 million yuan, a year-on-year decrease of 38.46% [29] - Canaan Technology's revenue was 560 million yuan, up 1.29% year-on-year [29] Group 10 - Metro Design reported a net profit of 221 million yuan, a year-on-year increase of 6.58% [30] - Metro Design's revenue was 1.32 billion yuan, up 5.31% year-on-year [30] - China Shipbuilding Special Gas plans to use up to 2.9 billion yuan of idle funds for cash management [31] - The company intends to invest in safe, liquid, principal-protected products [31] Group 11 - Jiuchuang Biotechnology received a medical device registration certificate for its lupus anticoagulant detection kit [32] - The product is intended for in vitro qualitative detection of lupus anticoagulant in human plasma [32] - Xinowei's subsidiary received approval for clinical trials of its innovative drug [33] - The drug is a humanized monoclonal antibody intended for treating multiple cancers [33] Group 12 - Dongcheng Pharmaceutical's subsidiary received FDA approval for clinical trials of its targeted radiopharmaceutical [34] - The drug is intended for treating advanced prostate cancer [34] - Shandong Road and Bridge received approval to issue bonds up to 4 billion yuan [35] - The company specializes in road and bridge engineering construction [35] Group 13 - Diou Home plans to invest 500 million yuan to establish a subsidiary focused on generative AI [36] - The investment aims to transform the company into a full-stack industrial intelligent service provider [36] - Dayilong achieved a net profit of 90.87 million yuan, a year-on-year increase of 217.89% [37] - Dayilong's revenue was 957 million yuan, up 57.35% year-on-year [37] Group 14 - Chaohongji reported a net profit of 331 million yuan, a year-on-year increase of 44.34% [38] - Chaohongji's revenue was 4.10 billion yuan, up 19.54% year-on-year [38] - Taiji Group reported a net profit of 139 million yuan, a year-on-year decrease of 71.94% [39] - Taiji Group's revenue was 5.66 billion yuan, down 27.63% year-on-year [39] Group 15 - Suneng Co. reported a net profit of 93.19 million yuan, a year-on-year decrease of 90.13% [41] - Suneng Co.'s revenue was 5.57 billion yuan, down 17.15% year-on-year [41] - Three Gorges Water Conservancy reported a net profit of 47.93 million yuan, a year-on-year decrease of 79.07% [42] - Three Gorges Water Conservancy's revenue was 4.90 billion yuan, down 6.10% year-on-year [42] Group 16 - Furida reported a net profit of 108 million yuan, a year-on-year decrease of 15.16% [44] - Furida's revenue was 1.79 billion yuan, down 7.05% year-on-year [44] - Chenzhou Electric International achieved a net profit of 25.92 million yuan, a year-on-year increase of 29.55% [46] - Chenzhou Electric International's revenue was 1.96 billion yuan, up 1.26% year-on-year [46] Group 17 - Farlantek achieved a net profit of 122 million yuan, a year-on-year increase of 41.05% [47] - Farlantek's revenue was 1.18 billion yuan, up 46.63% year-on-year [47] - Huitai Medical reported a net profit of 425 million yuan, a year-on-year increase of 24.11% [48] - Huitai Medical's revenue was 1.21 billion yuan, up 21.26% year-on-year [48] Group 18 - Dameng Data's director is under investigation for suspected violations [49] - The company's daily operations remain normal [49] - Maiwei Co. reported a net profit of 394 million yuan, a year-on-year decrease of 14.59% [50] - Maiwei Co.'s revenue was 4.21 billion yuan, down 13.48% year-on-year [50] Group 19 - Waiservice Holdings achieved a net profit of 384 million yuan, a year-on-year increase of 5.51% [52] - Waiservice Holdings' revenue was 12.25 billion yuan, up 16.15% year-on-year [52] - Huakang Co. reported a net profit of 134 million yuan, a year-on-year decrease of 3.38% [53] - Huakang Co.'s revenue was 1.87 billion yuan, up 37.32% year-on-year [53] Group 20 - Bluelight Optical achieved a net profit of 103 million yuan, a year-on-year increase of 110.27% [54] - Bluelight Optical's revenue was 577 million yuan, up 52.54% year-on-year [54] - Shunwang Technology reported a net profit of 162 million yuan, a year-on-year increase of 69.22% [55] - Shunwang Technology's revenue was 1.01 billion yuan, up 25.09% year-on-year [55] Group 21 - Anbiping reported a net loss of 12.50 million yuan in the first half of 2025 [56] - Anbiping's revenue was 159 million yuan, down 30.11% year-on-year [56] - Jinhua Co. reported a net profit of 6.20 million yuan, a year-on-year decrease of 34.53% [57] - Jinhua Co.'s revenue was 241 million yuan, down 1.90% year-on-year [57] Group 22 - Xiehe Electronics achieved a net profit of 28.96 million yuan, a year-on-year decrease of 8.31% [59] - Xiehe Electronics' revenue was 451 million yuan, up 12.13% year-on-year [59] - Huguang Co. reported a net profit of 276 million yuan, a year-on-year increase of 8.40% [60] - Huguang Co.'s revenue was 3.63 billion yuan, up 6.20% year-on-year [60]